309 related articles for article (PubMed ID: 20636842)
21. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry.
Seth A; Sinha N; Parikh K; Patel T; Hiremath MS; Mehta AB; Chandra P; Pinto B; Sethi KK; Sengottuvelu S
Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012
[TBL] [Abstract][Full Text] [Related]
24. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.
Bonello L; de Labriolle A; Roy P; Steinberg DH; Pinto Slottow TL; Xue Z; Kaneshige K; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2009; 10(3):156-61. PubMed ID: 19595396
[TBL] [Abstract][Full Text] [Related]
25. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
26. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
[TBL] [Abstract][Full Text] [Related]
27. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
[TBL] [Abstract][Full Text] [Related]
28. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
29. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
30. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
[TBL] [Abstract][Full Text] [Related]
31. Bivalirudin for patients with acute coronary syndromes.
Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
[TBL] [Abstract][Full Text] [Related]
32. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.
Ray MJ; Juneja M; Bett N; Walters DL
EuroIntervention; 2009 Aug; 5(3):330-5. PubMed ID: 19736157
[TBL] [Abstract][Full Text] [Related]
33. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
[TBL] [Abstract][Full Text] [Related]
34. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
[TBL] [Abstract][Full Text] [Related]
36. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
37. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
[TBL] [Abstract][Full Text] [Related]
38. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Chacko M; Lincoff AM; Wolski KE; Cohen DJ; Bittl JA; Lansky AJ; Tsuchiya Y; Betriu A; Yen MH; Chew DP; Cho L; Topol EJ
Am Heart J; 2006 May; 151(5):1032.e1-7. PubMed ID: 16644331
[TBL] [Abstract][Full Text] [Related]
39. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction.
Chu WW; Kuchulakanti PK; Wang B; Torguson R; Clavijo LC; Pichard AD; Suddath WO; Satler LF; Kent KM; Waksman R
Cardiovasc Revasc Med; 2006; 7(3):132-5. PubMed ID: 16945819
[TBL] [Abstract][Full Text] [Related]
40. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
Gibson CM; Ten Y; Murphy SA; Ciaglo LN; Southard MC; Lincoff AM; Waksman R
Am J Cardiol; 2007 Jun; 99(12):1687-90. PubMed ID: 17560876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
